New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment - Seite 3

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 106 locations in 53 countries as at September 30, 2023. For further information about ICON, visit: www.iconplc.com.

ICON/ICLR-G

¹ Source: Obesity. https://www.who.int/news-room/facts-in-pictures/detail/6-facts-on-obes ...

² Source: Global data: https://www.globaldata.com/data-insights/healthcare/number-of-ongoing- ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20240124995130/en/

The Icon Stock at the time of publication of the news with a raise of +1,20 % to 245,3EUR on Tradegate stock exchange (23. Januar 2024, 12:05 Uhr).